Name: ABSA’s 1st Biosecurity Symposium
Start: 2021-04-20T00:00:00-05:00
End: 2021-04-23T23:59:59-05:00
Location: Renaissance Depot Hotel

FDA Authorizes Moderna COVID-19 mRNA Vaccine for Emergency Use

Altimmune Poised to Begin Phase 1 Clinical Trial of Single-Dose Intranasal COVID-19 Vaccine

Celdara’s Pandemic Security Initiative Introduces Scientific Advisory Board Founding Members

by Global Biodefense Staff November 5, 2020, 6:31 pm
InBios Awarded $12.7M to Boost Production of Two COVID-19 Diagnostics

by Global Biodefense Staff October 31, 2020, 11:27 am
Regeneron Halts Trial for Antibody Cocktail in Sickest COVID-19 Patients

by Global Biodefense Staff October 30, 2020, 1:05 pm
Inspirotec Expands Into RFU Innovation and Research Park

by Global Biodefense Staff October 21, 2020, 9:07 am
Centivax Licenses Anti-COVID-19 Antibodies to Thermo Fisher

by Global Biodefense Staff October 20, 2020, 2:34 pm
CRDF Global Selected to Support Biological Threat Reduction Program Contracts

by Global Biodefense Staff October 19, 2020, 4:06 pm
FDA Approves First Ebola Therapeutic

by Global Biodefense Staff October 15, 2020, 6:49 pm
MIS-C Detection: BARDA Invests in Rapid Diagnostic for Pediatric Complication of SARS-CoV-2

by Global Biodefense Staff October 15, 2020, 10:46 am
U.S. Invests in Pandemic Vaccine Manufacturing Capacity with $31M Contract to Cytiva

by Global Biodefense Staff October 15, 2020, 7:18 am
DoD Expands U.S. Domestic Diagnostics Capacity with $481M Cue Health Deal

by Global Biodefense Staff October 15, 2020, 5:04 am
Newsletter

Global Biodefense News

First Name

Last Name

Organization Type

Email address:

Don't worry, we don't spam
BARDA and JPEO-CBRND Back Cepheid’s Multiplex Test for Influenza, SARS-CoV2 and RSV

by Global Biodefense Staff October 8, 2020, 11:28 am
Harvard Wyss Institute Licenses Diagnostic Technologies to Agile Biodetection

by Global Biodefense Staff October 8, 2020, 7:36 am
Eli Lilly Says Antibody Combo Effective Against COVID, Asks for EUA

by Global Biodefense Staff October 7, 2020, 2:49 pm
NIH RADx Initiative Advances Six New COVID-19 Testing Technologies

by Global Biodefense Staff October 7, 2020, 9:25 am

Congratulations. You've reached the end of the internet.

Industry News

FDA Authorizes Moderna COVID-19 mRNA Vaccine for Emergency Use

Altimmune Poised to Begin Phase 1 Clinical Trial of Single-Dose Intranasal COVID-19 Vaccine

Celdara’s Pandemic Security Initiative Introduces Scientific Advisory Board Founding Members

InBios Awarded $12.7M to Boost Production of Two COVID-19 Diagnostics

Regeneron Halts Trial for Antibody Cocktail in Sickest COVID-19 Patients

Inspirotec Expands Into RFU Innovation and Research Park

Centivax Licenses Anti-COVID-19 Antibodies to Thermo Fisher

CRDF Global Selected to Support Biological Threat Reduction Program Contracts

FDA Approves First Ebola Therapeutic

MIS-C Detection: BARDA Invests in Rapid Diagnostic for Pediatric Complication of SARS-CoV-2

U.S. Invests in Pandemic Vaccine Manufacturing Capacity with $31M Contract to Cytiva

DoD Expands U.S. Domestic Diagnostics Capacity with $481M Cue Health Deal

BARDA and JPEO-CBRND Back Cepheid’s Multiplex Test for Influenza, SARS-CoV2 and RSV

Harvard Wyss Institute Licenses Diagnostic Technologies to Agile Biodetection

Eli Lilly Says Antibody Combo Effective Against COVID, Asks for EUA

NIH RADx Initiative Advances Six New COVID-19 Testing Technologies

Biodefense Headlines – 21 January 2021

First Cases of B.1.1.7 Variant COVID-19 Detected in Washington State

The Response Measures Database: Central Archive of COVID-19 Interventions

EU Initiative on Health Security Work Programme 2021

Rapid Identification of Ricin in Serum Samples Using LC–MS/MS

Dr. Fauci Makes First Appearance at Biden White House Press Briefing – Transcript

ASM Expresses Support for the Global Health Security Act of 2021

How and When Will Lower-Income Countries Gain Access to COVID-19 Vaccines?

OHDSI Awarded $10M FDA Contract to Monitor Safety and Effectiveness of Vaccines, Biologics

Neutralizing Norovirus: NIAID Monoclonal Antibodies Licensing Opportunity

NIAID Looks Ahead to Pan-Coronavirus Vaccine Candidates

DRIVE ReDIRECT: Program Seeks to Develop Countermeasures Against Chemical Threats

Emerging Infections Network – Managing Travelers Who Acquire Disease Abroad

Upcoming Events

Application Deadline: Expanding Existing Research Grants, CRADAs for Novel Coronavirus Response

Envisioning a Transformed Clinical Trials Enterprise for 2030 – Session 2

Systematizing the One Health Approach in Preparedness and Response Efforts for Infectious Disease Outbreaks

Envisioning a Transformed Clinical Trials Enterprise for 2030 – Session 3

ABSA’s 1st Biosecurity Symposium

Latest stories

Latest Articles